ymmetric Dimethyl
Asymmetric Dimethyl Arginine and
nitric oxide in chronic renal disease patients with cardiac and non cardiac
complications
Sahar Eladawy1;
Seham Sabry1 and Rayyh A.M.Saleh2
1Internal Medicine and 2Clinical
pathology Departments, Faculty of Medicine, Al Azhar University
e
Abstract: Asymmetrical dimethylarginine (ADMA) is inhibitor of
nitric-oxide synthase, which has been linked to endothelial dysfunction and
atherosclerosis in the general population, is raised in patients with end-stage
renal disease and could contribute to the high cardiovascular risk in patients
with chronic renal failure. Aim of the work, the aim of this study is to
evaluate the levels of ADMA and NO and their association with cardiovascular
disease in chronic renal disease patients. Patient and methods. Thirty patients
with chronic renal failure under hemodialysis three setions//week and fifteen
apparently healthy individuals as a control group .they were selected from
internal medicine department (nephrology unit), Al Zahra university hospital
underwent. Complete history taking, full clinical examination, laboratory
investigations as complete blood picture, blood urea, serum creatinine, serum
Na, serum K, cholesterol, triglyceride, echocardiography, ADMA, NO. Conclusion,
Elevated plasma ADMA level in the chronic renal failure patients. Also plasma
ADMA levels predict cardiovascular events in patients with chronic renal
failure.
[Sahar Eladawy, Seham Sabry and Rayyh A.M.Saleh. Asymmetric
Dimethyl Arginine and nitric oxide in chronic renal disease patients with
cardiac and non cardiac complications. J
Am Sci 2012;8(10):861-865]. (ISSN: 1545-1003). http://www.jofamericanscience.org. 115
